Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing

Juliane Scholz, Kai Grossmann, Ilka Knütter, Rico Hiemann, Mandy Sowa, Nadja Röber, Stefan Rödiger, Peter Schierack, Dirk Reinhold, Dimitrios P. Bogdanos, Pier Luigi Meroni, Antonella Radice, Karsten Conrad, Dirk Roggenbuck

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: For the serological diagnosis of systemic autoimmune rheumatic diseases, a two-tier approach starting with sensitive antinuclear antibody (ANA) detection by indirect immunofluorescence (IIF) on HEp-2 cells followed by characterization of positive findings with different immunoassays is recommended. To overcome drawbacks of this approach, we developed a novel technique allowing the combination of screening and simultaneous confirmatory testing. For the first time, this creates the basis for second generation ANA testing. Methods: ANA and autoantibodies (autoAbs) to double-stranded DNA (dsDNA), CENP-B, SS-A/Ro52, SS-A/Ro60, SS-B/La, RNP-Sm, Sm, and Scl-70 were determined by IIF and enzyme-linked immunosorbent assay (ELISA), respectively, and compared to simultaneous analysis thereof by second generation ANA analysis in patients with systemic lupus erythematosus (n=174), systemic sclerosis (n=103), Sjögren's syndrome (n=46), rheumatoid arthritis (n=36), mixed and undetermined connective tissue diseases (n=13), myositis (n=21), infectious disease (n=21), autoimmune liver disease (n=93), inflammatory bowel disease (n=78), paraproteinemia (n=11), and blood donors (n=101). Results: There was very good agreement of second generation ANA testing with classical one by IIF and ELISA regarding testing for ANA and autoAbs to dsDNA, CENP-B, SS-B, RNP-Sm, Scl-70, SS-A/Ro52, and SS-A/Ro60 (Cohen's κ>0.8). The agreement for anti-Sm autoAb was good (κ=0.77). The differences of both approaches were not significant for autoAbs to SS-B/La, RNP-Sm, Scl-70, SS-A/Ro60, and SS-A/Ro52 (McNemar's test, p>0.05, respectively). Conclusions: Second generation ANA testing can replace the two-tier analysis by combining IIF screening with multiplex confirmative testing. This addresses shortcomings of classical ANA analysis like false-negative ANA findings and lack of laboratory efficiency and standardization.

Original languageEnglish
Pages (from-to)1991-2002
Number of pages12
JournalClinical Chemistry and Laboratory Medicine
Volume53
Issue number12
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Antinuclear Antibodies
Screening
Testing
Indirect Fluorescent Antibody Technique
Autoantibodies
Immunosorbents
Autoimmune Diseases
Assays
Enzyme-Linked Immunosorbent Assay
Mixed Connective Tissue Disease
Paraproteinemias
Myositis
Systemic Scleroderma
Enzymes
Rheumatic Diseases
Blood Donors
Inflammatory Bowel Diseases
Immunoassay
Systemic Lupus Erythematosus
Liver

Keywords

  • antinuclear antibody
  • digital fluorescence
  • second generation ANA testing
  • standardization
  • systemic autoimmune rheumatic disease

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Scholz, J., Grossmann, K., Knütter, I., Hiemann, R., Sowa, M., Röber, N., ... Roggenbuck, D. (2015). Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing. Clinical Chemistry and Laboratory Medicine, 53(12), 1991-2002. https://doi.org/10.1515/cclm-2015-0083

Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing. / Scholz, Juliane; Grossmann, Kai; Knütter, Ilka; Hiemann, Rico; Sowa, Mandy; Röber, Nadja; Rödiger, Stefan; Schierack, Peter; Reinhold, Dirk; Bogdanos, Dimitrios P.; Meroni, Pier Luigi; Radice, Antonella; Conrad, Karsten; Roggenbuck, Dirk.

In: Clinical Chemistry and Laboratory Medicine, Vol. 53, No. 12, 01.11.2015, p. 1991-2002.

Research output: Contribution to journalArticle

Scholz, J, Grossmann, K, Knütter, I, Hiemann, R, Sowa, M, Röber, N, Rödiger, S, Schierack, P, Reinhold, D, Bogdanos, DP, Meroni, PL, Radice, A, Conrad, K & Roggenbuck, D 2015, 'Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing', Clinical Chemistry and Laboratory Medicine, vol. 53, no. 12, pp. 1991-2002. https://doi.org/10.1515/cclm-2015-0083
Scholz, Juliane ; Grossmann, Kai ; Knütter, Ilka ; Hiemann, Rico ; Sowa, Mandy ; Röber, Nadja ; Rödiger, Stefan ; Schierack, Peter ; Reinhold, Dirk ; Bogdanos, Dimitrios P. ; Meroni, Pier Luigi ; Radice, Antonella ; Conrad, Karsten ; Roggenbuck, Dirk. / Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing. In: Clinical Chemistry and Laboratory Medicine. 2015 ; Vol. 53, No. 12. pp. 1991-2002.
@article{193e2afa4bc148a69b274462459494d8,
title = "Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing",
abstract = "Background: For the serological diagnosis of systemic autoimmune rheumatic diseases, a two-tier approach starting with sensitive antinuclear antibody (ANA) detection by indirect immunofluorescence (IIF) on HEp-2 cells followed by characterization of positive findings with different immunoassays is recommended. To overcome drawbacks of this approach, we developed a novel technique allowing the combination of screening and simultaneous confirmatory testing. For the first time, this creates the basis for second generation ANA testing. Methods: ANA and autoantibodies (autoAbs) to double-stranded DNA (dsDNA), CENP-B, SS-A/Ro52, SS-A/Ro60, SS-B/La, RNP-Sm, Sm, and Scl-70 were determined by IIF and enzyme-linked immunosorbent assay (ELISA), respectively, and compared to simultaneous analysis thereof by second generation ANA analysis in patients with systemic lupus erythematosus (n=174), systemic sclerosis (n=103), Sj{\"o}gren's syndrome (n=46), rheumatoid arthritis (n=36), mixed and undetermined connective tissue diseases (n=13), myositis (n=21), infectious disease (n=21), autoimmune liver disease (n=93), inflammatory bowel disease (n=78), paraproteinemia (n=11), and blood donors (n=101). Results: There was very good agreement of second generation ANA testing with classical one by IIF and ELISA regarding testing for ANA and autoAbs to dsDNA, CENP-B, SS-B, RNP-Sm, Scl-70, SS-A/Ro52, and SS-A/Ro60 (Cohen's κ>0.8). The agreement for anti-Sm autoAb was good (κ=0.77). The differences of both approaches were not significant for autoAbs to SS-B/La, RNP-Sm, Scl-70, SS-A/Ro60, and SS-A/Ro52 (McNemar's test, p>0.05, respectively). Conclusions: Second generation ANA testing can replace the two-tier analysis by combining IIF screening with multiplex confirmative testing. This addresses shortcomings of classical ANA analysis like false-negative ANA findings and lack of laboratory efficiency and standardization.",
keywords = "antinuclear antibody, digital fluorescence, second generation ANA testing, standardization, systemic autoimmune rheumatic disease",
author = "Juliane Scholz and Kai Grossmann and Ilka Kn{\"u}tter and Rico Hiemann and Mandy Sowa and Nadja R{\"o}ber and Stefan R{\"o}diger and Peter Schierack and Dirk Reinhold and Bogdanos, {Dimitrios P.} and Meroni, {Pier Luigi} and Antonella Radice and Karsten Conrad and Dirk Roggenbuck",
year = "2015",
month = "11",
day = "1",
doi = "10.1515/cclm-2015-0083",
language = "English",
volume = "53",
pages = "1991--2002",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH",
number = "12",

}

TY - JOUR

T1 - Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing

AU - Scholz, Juliane

AU - Grossmann, Kai

AU - Knütter, Ilka

AU - Hiemann, Rico

AU - Sowa, Mandy

AU - Röber, Nadja

AU - Rödiger, Stefan

AU - Schierack, Peter

AU - Reinhold, Dirk

AU - Bogdanos, Dimitrios P.

AU - Meroni, Pier Luigi

AU - Radice, Antonella

AU - Conrad, Karsten

AU - Roggenbuck, Dirk

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background: For the serological diagnosis of systemic autoimmune rheumatic diseases, a two-tier approach starting with sensitive antinuclear antibody (ANA) detection by indirect immunofluorescence (IIF) on HEp-2 cells followed by characterization of positive findings with different immunoassays is recommended. To overcome drawbacks of this approach, we developed a novel technique allowing the combination of screening and simultaneous confirmatory testing. For the first time, this creates the basis for second generation ANA testing. Methods: ANA and autoantibodies (autoAbs) to double-stranded DNA (dsDNA), CENP-B, SS-A/Ro52, SS-A/Ro60, SS-B/La, RNP-Sm, Sm, and Scl-70 were determined by IIF and enzyme-linked immunosorbent assay (ELISA), respectively, and compared to simultaneous analysis thereof by second generation ANA analysis in patients with systemic lupus erythematosus (n=174), systemic sclerosis (n=103), Sjögren's syndrome (n=46), rheumatoid arthritis (n=36), mixed and undetermined connective tissue diseases (n=13), myositis (n=21), infectious disease (n=21), autoimmune liver disease (n=93), inflammatory bowel disease (n=78), paraproteinemia (n=11), and blood donors (n=101). Results: There was very good agreement of second generation ANA testing with classical one by IIF and ELISA regarding testing for ANA and autoAbs to dsDNA, CENP-B, SS-B, RNP-Sm, Scl-70, SS-A/Ro52, and SS-A/Ro60 (Cohen's κ>0.8). The agreement for anti-Sm autoAb was good (κ=0.77). The differences of both approaches were not significant for autoAbs to SS-B/La, RNP-Sm, Scl-70, SS-A/Ro60, and SS-A/Ro52 (McNemar's test, p>0.05, respectively). Conclusions: Second generation ANA testing can replace the two-tier analysis by combining IIF screening with multiplex confirmative testing. This addresses shortcomings of classical ANA analysis like false-negative ANA findings and lack of laboratory efficiency and standardization.

AB - Background: For the serological diagnosis of systemic autoimmune rheumatic diseases, a two-tier approach starting with sensitive antinuclear antibody (ANA) detection by indirect immunofluorescence (IIF) on HEp-2 cells followed by characterization of positive findings with different immunoassays is recommended. To overcome drawbacks of this approach, we developed a novel technique allowing the combination of screening and simultaneous confirmatory testing. For the first time, this creates the basis for second generation ANA testing. Methods: ANA and autoantibodies (autoAbs) to double-stranded DNA (dsDNA), CENP-B, SS-A/Ro52, SS-A/Ro60, SS-B/La, RNP-Sm, Sm, and Scl-70 were determined by IIF and enzyme-linked immunosorbent assay (ELISA), respectively, and compared to simultaneous analysis thereof by second generation ANA analysis in patients with systemic lupus erythematosus (n=174), systemic sclerosis (n=103), Sjögren's syndrome (n=46), rheumatoid arthritis (n=36), mixed and undetermined connective tissue diseases (n=13), myositis (n=21), infectious disease (n=21), autoimmune liver disease (n=93), inflammatory bowel disease (n=78), paraproteinemia (n=11), and blood donors (n=101). Results: There was very good agreement of second generation ANA testing with classical one by IIF and ELISA regarding testing for ANA and autoAbs to dsDNA, CENP-B, SS-B, RNP-Sm, Scl-70, SS-A/Ro52, and SS-A/Ro60 (Cohen's κ>0.8). The agreement for anti-Sm autoAb was good (κ=0.77). The differences of both approaches were not significant for autoAbs to SS-B/La, RNP-Sm, Scl-70, SS-A/Ro60, and SS-A/Ro52 (McNemar's test, p>0.05, respectively). Conclusions: Second generation ANA testing can replace the two-tier analysis by combining IIF screening with multiplex confirmative testing. This addresses shortcomings of classical ANA analysis like false-negative ANA findings and lack of laboratory efficiency and standardization.

KW - antinuclear antibody

KW - digital fluorescence

KW - second generation ANA testing

KW - standardization

KW - systemic autoimmune rheumatic disease

UR - http://www.scopus.com/inward/record.url?scp=84946882239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946882239&partnerID=8YFLogxK

U2 - 10.1515/cclm-2015-0083

DO - 10.1515/cclm-2015-0083

M3 - Article

VL - 53

SP - 1991

EP - 2002

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 12

ER -